Market research
MCRB Seres Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 46M
- P/E ratio
- Not available
- Analyst target
- 17
- Dividend yield
- Not available
- Beta
- 0.21
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US81750R2013
- Market cap
- 46M
- P/E ratio
- Not available
- Analyst target
- 17
- Dividend yield
- Not available
- Beta
- 0.21
About
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MCRB discussion.
5 years, 4 months ago
Seres Therapeutics, Inc is currently in a long term downtrend where the price is trading 18.1% below its 200 day moving average.
From a valuation standpoint, the stock is 96.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 49.5.
Seres Therapeutics, Inc's total revenue rose by 130.4% to $18M since the same quarter in the previous year.
Its net income has increased by 2.8% to $-18M since the same quarter in the previous year.
Finally, its free cash flow fell by 27.1% to $-18M since the same quarter in the previous year.
Based on the above factors, Seres Therapeutics, Inc gets an overall score of 3/5.